Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Buy
59
DXCM Quote, Financials, Valuation and Earnings
Last price:
$84.39
Seasonality move
:
6.58%
Day range:
$83.89 - $86.33
52-week range:
$62.34 - $142.00
Dividend yield:
0%
P/E ratio:
50.53x
P/S ratio:
8.86x
P/B ratio:
16.65x
Volume:
5.1M
Avg. volume:
3.5M
1-year change:
-32.74%
Market cap:
$33B
Revenue:
$3.6B
EPS (TTM):
$1.67
Analysts' Opinion
-
Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $97.14, DexCom has an estimated upside of 15.12% from its current price of $84.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 11.12% downside risk from its current price of $84.38.
Fair Value
-
According to the consensus of 20 analysts, DexCom has 15.12% upside to fair value with a price target of $97.14 per share.
DXCM vs. S&P 500
-
Over the past 5 trading days, DexCom has overperformed the S&P 500 by 5.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
DexCom does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
DexCom has grown year-over-year revenues for 0 quarters straight. In the most recent quarter DexCom reported revenues of $994.2M.
Earnings Growth
-
DexCom has grown year-over-year earnings for 6 quarters straight. In the most recent quarter DexCom reported earnings per share of $0.34.
Enterprise value:
32.9B
EV / Invested capital:
--
Price / LTM sales:
8.86x
EV / EBIT:
43.13x
EV / Revenue:
8.32x
PEG ratio (5yr expected):
0.61x
EV / Free cash flow:
61.51x
Price / Operating cash flow:
65.49x
Enterprise value / EBITDA:
33.74x
Gross Profit (TTM):
$2.4B
Return On Assets:
10.48%
Net Income Margin (TTM):
17.22%
Return On Equity:
30.96%
Return On Invested Capital:
14.61%
Operating Margin:
15.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.8B | $3.4B | $4B | $975M | $994.2M | |
| Gross Profit | $1.8B | $2.2B | $2.4B | $623.3M | $593.8M | |
| Operating Income | $266.4M | $506.2M | $628M | $205.5M | $152M | |
| EBITDA | $434.4M | $787.3M | $975.3M | $293.5M | $237.4M | |
| Diluted EPS | $0.54 | $0.91 | $1.67 | $0.29 | $0.34 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.2B | $3.7B | $3.4B | $4.7B | $4.3B | |
| Total Assets | $3.8B | $4.8B | $4.9B | $6.6B | $6.4B | |
| Current Liabilities | $506.4M | $734.9M | $900.5M | $1.7B | $1.7B | |
| Total Liabilities | $2.3B | $2.6B | $3.1B | $4.3B | $4.4B | |
| Total Equity | $1.5B | $2.1B | $1.8B | $2.3B | $2B | |
| Total Debt | $1.6B | $1.7B | $2B | $2.6B | $2.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $642.8M | $747.4M | $821.7M | $269.2M | $199.5M | |
| Cash From Investing | -$823.5M | -$1.1B | $511.1M | -$179.5M | $210.3M | |
| Cash From Financing | -$552.3M | $312.3M | -$1.4B | -$637.4M | -$736.5M | |
| Free Cash Flow | $261.3M | $499.8M | $535M | $218.8M | $88.3M | |
DXCM
Sector
Market Cap
$33B
$45.4M
Price % of 52-Week High
59.42%
46.67%
Dividend Yield
0%
0%
Shareholder Yield
5.25%
-0.74%
1-Year Price Total Return
-32.74%
-33.9%
Beta (5-Year)
1.128
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$80.73
200-day SMA
Sell
Level
$92.85
Bollinger Bands (100)
Buy
Level
68.84 - 78.4
Chaikin Money Flow
Buy
Level
108.9M
20-day SMA
Buy
Level
$79.64
Relative Strength Index (RSI14)
Buy
Level
63.45
ADX Line
Buy
Level
26.67
Williams %R
Sell
Level
-15.3423
50-day SMA
Buy
Level
$77.38
MACD (12, 26)
Buy
Level
1.35
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
129.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.5799)
Buy
CA Score
(Annual)
Level (-0.2973)
Buy
Beneish M-Score
(Annual)
Level (-2.3878)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.4823)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Stock Forecast FAQ
In the current month, DXCM has received 16 Buy ratings 4 Hold ratings, and 0 Sell ratings. The DXCM average analyst price target in the past 3 months is $97.14.
-
Where Will DexCom Stock Be In 1 Year?
According to analysts, the consensus estimate is that DexCom share price will rise to $97.14 per share over the next 12 months.
-
What Do Analysts Say About DexCom?
Analysts are divided on their view about DexCom share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DexCom is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is DexCom's Price Target?
The price target for DexCom over the next 1-year time period is forecast to be $97.14 according to 20 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is DXCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for DexCom is a Buy. 16 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DXCM?
You can purchase shares of DexCom via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DexCom shares.
-
What Is The DexCom Share Price Today?
DexCom was last trading at $84.39 per share. This represents the most recent stock quote for DexCom. Yesterday, DexCom closed at $84.38 per share.
-
How To Buy DexCom Stock Online?
In order to purchase DexCom stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
NUTX alert for Jan 18
Nutex Health [NUTX] is up 2.83% over the past day.
Buy
53
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Sell
34
NGVT alert for Jan 18
Ingevity [NGVT] is up 1.31% over the past day.
